Protalix BioTherapeutics (PLX) Receivables (2010 - 2026)

Protalix BioTherapeutics' Receivables history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Receivables fell 37.13% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 37.13% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, up 203.88% from the prior year.
• Receivables eased to $2.9 million in Q1 2026 per PLX's latest filing, from $8.8 million in the prior quarter.
• Across five years, Receivables topped out at $14.4 million in Q3 2025 and bottomed at $1.3 million in Q1 2023.
• The 5-year median for Receivables is $4.7 million (2025), against an average of $5.9 million.
• Across the five-year window, Receivables slumped 77.93% in 2023 and jumped 557.18% in 2025, its largest moves.
• Year by year, Receivables stood at $4.6 million in 2022, then increased by 14.96% to $5.3 million in 2023, then plunged by 44.82% to $2.9 million in 2024, then surged by 203.88% to $8.8 million in 2025, then slumped by 66.75% to $2.9 million in 2026.
• Per Business Quant, the three latest PLX Receivables figures stand at $2.9 million (Q1 2026), $8.8 million (Q4 2025), and $14.4 million (Q3 2025).